Published by Global Banking & Finance Review®
Posted on July 16, 2025
2 min readLast updated: January 22, 2026
Add as preferred source on GoogleGerresheimer halts sale talks due to market challenges, affecting shares and future growth. Strategic review of glass business planned.
MUNICH (Reuters) -German packaging and medical equipment maker Gerresheimer has ended discussions on a potential sale of the company after months of talks since the start of 2025, it said on Wednesday evening.
In February the Duesseldorf-based company had said it was in early discussions with private equity investors over a potential sale, with KPS Capital Partners and Warburg Pincus among the possible buyers.
Among Gerresheimer activities to catch attention is its production of pens used for injecting weight-loss medication such as Novo Nordisk's Wegovy.
"After a thorough analysis ... the company believes that continuing the discussions is not in the best interest of the company and its stakeholders," Gerresheimer's statement said.
Gerresheimer shares fell 6% in late trading on Tradegate after the announcement.
The company has struggled in the face of weak demand in cosmetics and oral liquids markets, which led it to cut the lower end of its revenue growth forecast for 2025 last week, now estimating a range of 0-2% growth, down from the previous range of 1% to 2%.
The company will, however, provide a strategic review of its moulded glass business on October 15, it said, a segment that it could decide to spin off.
In the medium term, Gerresheimer expects organic revenue growth of 6-9% and an organic adjusted EBITDA margin of 23-25%, it said in Wednesday's statement.
(Reporting by Alexander Hübner and Matthias Williams; Editing by David Goodman and Sandra Maler)
Gerresheimer concluded that continuing the discussions was not in the best interest of the company and its stakeholders after a thorough analysis.
Following the announcement, Gerresheimer shares fell by 6% in late trading on Tradegate.
In the medium term, Gerresheimer expects organic revenue growth of 6-9% and an organic adjusted EBITDA margin of 23-25%.
The company has struggled with weak demand in the cosmetics and oral liquids markets, prompting it to cut the lower end of its revenue growth forecast for 2025.
Gerresheimer plans to provide a strategic review of its moulded glass business on October 15.
Explore more articles in the Finance category
